Sobi Ups 2016 Revenue Expectations Marking A Year Of Evolution
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum AB (Sobi) has updated its earnings outlook for this year following a positive recommendation for approval of its Biogen-partnered hemophilia B product, Alprolix (rFIXFc), in Europe.